Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02262741 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02262741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02262741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
October 15, 2014
Completion date
September 21, 2017
Enrollment
71 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck